PMID- 28319414
OWN - NLM
STAT- MEDLINE
DCOM- 20171116
LR  - 20181202
IS  - 0006-9248 (Print)
IS  - 0006-9248 (Linking)
VI  - 118
IP  - 3
DP  - 2017
TI  - Preparation and characterization of ZnO nanoparticles coated by chitosan-linoleic 
      acid; fungal growth and biofilm assay.
PG  - 169-174
LID - 10.4149/BLL_2017_034 [doi]
AB  - INTRODUCTION: This study has been carried out on reviewing the use of new 
      synthetic component of zinc oxide nanoparticles (ZnO NPs) coated by 
      Chitosan-linoleic acid (CS-LA) and to assess Minimum inhibitory concentration 
      (MIC) of nanoparticles on clinical samples and biofilm formation in vitro. 
      MATERIALS AND METHODS: At first the synthesized ZnO NPs coated by CS-LA were 
      identified with X-ray powder diffraction (XRD), Scanning electron microscope 
      (SEM), Transmission electron microscope (TEM) and Fourier Transform Infrared 
      Spectroscopy analysis (FTIR).Through in vitro tests, the value of MIC and Minimum 
      fungicide concentration (MFC) of nanoparticles and standard and clinical strains 
      of candida were evaluated in comparison with fluconazole as the control group 
      using the CLSI-M27 method. Finally, biofilm formation was studied using MTT 
      assay. RESULT: The results showed that MIC50 of fluconazole and nanoparticle in 
      clinical strains was 64 microg/ml and 128 microg/ml, respectively. The MIC of fluconazole 
      and nanoparticle in C. albicans (ATCC10231) was 8 microg/ml and 32 microg/ml 
      respectively. The MFC of nanoparticle and fluconazole for clinical samples was 
      recorded at similar level (128 mug/ml). MTT results indicated that the capacity of 
      inhibition of biofilm formation was 43.07 % and 36.68 % by ZnO NPs and 
      fluconazole, respectively. CONCLUSION: It is concluded that the new synthesized 
      nanoparticle has appropriate efficacy compared with fluconazole in inhibitory 
      activity on C. albicans growth and biofilm formation. As a result, ZnO NPs can be 
      introduced as an effective agent for diminishing adhesion capacity of C. albicans 
      (Tab. 1, Fig. 4, Ref. 26).
FAU - Barad, S
AU  - Barad S
FAU - Roudbary, M
AU  - Roudbary M
FAU - Omran, A Nasrollahi
AU  - Omran AN
FAU - Daryasari, M Porgham
AU  - Daryasari MP
LA  - eng
PT  - Journal Article
PL  - Slovakia
TA  - Bratisl Lek Listy
JT  - Bratislavske lekarske listy
JID - 0065324
RN  - 0 (Antifungal Agents)
RN  - 8VZV102JFY (Fluconazole)
RN  - 9012-76-4 (Chitosan)
RN  - 9KJL21T0QJ (Linoleic Acid)
RN  - SOI2LOH54Z (Zinc Oxide)
SB  - IM
MH  - Antifungal Agents/pharmacology
MH  - Biofilms/*drug effects
MH  - Candida albicans/*drug effects/ultrastructure
MH  - Chitosan/*pharmacology
MH  - Fluconazole/pharmacology
MH  - Linoleic Acid/*pharmacology
MH  - Microbial Sensitivity Tests
MH  - Microscopy, Electron, Scanning
MH  - Microscopy, Electron, Transmission
MH  - Nanoparticles/ultrastructure
MH  - Spectroscopy, Fourier Transform Infrared
MH  - X-Ray Diffraction
MH  - Zinc Oxide/*pharmacology
OTO - NOTNLM
OT  - Candida biofilm antifungal.
OT  - chitosan
OT  - linoleic acid
OT  - zinc oxide
EDAT- 2017/03/21 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/03/21 06:00
PHST- 2017/03/21 06:00 [entrez]
PHST- 2017/03/21 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - 10.4149/BLL_2017_034 [doi]
PST - ppublish
SO  - Bratisl Lek Listy. 2017;118(3):169-174. doi: 10.4149/BLL_2017_034.